Product logins

Find logins to all Clarivate products below.


Treatment Algorithms in Atrial Fibrillation | Treatment Algorithms | Claims Data Analysis | US | 2015

For the estimated 4.9 million people in the United States who suffer from atrial fibrillation (AF), there are a number of different treatment approaches that can be utilized, each with a wide range of available pharmacological options. The AHA/ACCF/HRS guidelines recommend the implementation of rate control therapy to control heart rate, plus rhythm control treatment to establish a normal sinus rhythm for appropriate patients. The use of rate and/or rhythm control is usually accompanied by antithrombotic therapy for stroke risk reduction in at-risk patients. Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in newly diagnosed and recently treated AF populations. Concerning newly diagnosed patients, the report provides a quantitative analysis of treatment patterns and patient share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. With respect to recently treated patients, the report quantifies a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliancy by brand.

Related Market Assessment Reports

Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…